Rhinovirus Clinical Trial
Official title:
Impact of Covid-19 Pandemic on the Epidemiology of Rhinovirus
Rhinovirus (RV) has long been known as the main etiological agent of "common colds" among children and adults. Indeed, RV is involved in more than 50% of upper respiratory tract infections (URTIs), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. RV can also cause mild to severe lower respiratory tract infections (LRTIs) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. RV circulates worldwide, especially in temperate climate zones (i.e. many areas of the USA and Europe) and is responsible for annual outbreaks from early fall to the end of spring. The covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. For example, the winter Respiratory Syncytial Virus (RSV) epidemic in Lyon, France, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. This can be explained by the widespread deployment of barrier gestures and social distancing measures, known as "non pharmacological interventions" (NPI). However, the Covid-19 pandemic doesn't seem to have the same reducing impact on Rhinovirus epidemic. A better understanding of viral interactions and factors influencing RV epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of Rhinovirus.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02984280 -
Specific Respiratory Infections as Triggers of Acute Medical Events
|
N/A | |
| Completed |
NCT01158560 -
A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections
|
Phase 3 | |
| Completed |
NCT03605862 -
Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
|
Phase 3 | |
| Recruiting |
NCT06149494 -
RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory Infection
|
Phase 2 | |
| Not yet recruiting |
NCT05348616 -
Impact of the Covid-19 on RSV
|
||
| Recruiting |
NCT04489381 -
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
|
Phase 3 | |
| Completed |
NCT04670627 -
Biomarkers in Nasal Samples of Seasonal Allergic Rhinitics
|
||
| Suspended |
NCT03508479 -
Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection
|
Phase 1 | |
| Not yet recruiting |
NCT05348655 -
Impact of the Covid-19 on RSV Epidemic in the Metropolis of Lyon
|
||
| Completed |
NCT02438293 -
'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'
|
||
| Completed |
NCT05016687 -
First-in-human Clinical Trial Evaluating CUR-N399 in Healthy Volunteers.
|
Phase 1 | |
| Completed |
NCT02660489 -
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma
|
Phase 2 | |
| Completed |
NCT02522832 -
Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge
|
N/A | |
| Completed |
NCT01302418 -
Collection and Testing of Respiratory Samples
|
N/A | |
| Completed |
NCT01249625 -
The Respiratory Protection Effectiveness Clinical Trial
|
N/A | |
| Completed |
NCT01175226 -
A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
|
Phase 2 | |
| Completed |
NCT00394914 -
Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295)
|
Phase 2 | |
| Withdrawn |
NCT03024177 -
A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
|
Phase 2 |